These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 30032830)

  • 21. Factors affecting crizotinib-induced hepatotoxicity in non-small cell lung cancer patients.
    Jung D; Han JM; Yee J; Kim JY; Gwak HS
    Med Oncol; 2018 Oct; 35(12):154. PubMed ID: 30367285
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term Survival Associated with Crizotinib in a Lung Cancer Patient with a Pulmonary Artery Embolism.
    Shen Q; Dong XQ; Zhou JY
    Chin Med J (Engl); 2018 Jan; 131(1):111-112. PubMed ID: 29271393
    [No Abstract]   [Full Text] [Related]  

  • 23. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.
    Croegaert K; Kolesar JM
    Am J Health Syst Pharm; 2015 Sep; 72(17):1456-62. PubMed ID: 26294238
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful treatment with ceritinib after crizotinib induced hepatitis.
    Sassier M; Mennecier B; Gschwend A; Rein M; Coquerel A; Humbert X; Alexandre J; Fedrizzi S; Gervais R
    Lung Cancer; 2016 May; 95():15-6. PubMed ID: 27040846
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
    Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus.
    Cappuzzo F; Moro-Sibilot D; Gautschi O; Boleti E; Felip E; Groen HJ; Germonpré P; Meldgaard P; Arriola E; Steele N; Fox J; Schnell P; Engelsberg A; Wolf J
    Lung Cancer; 2015 Feb; 87(2):89-95. PubMed ID: 25576294
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
    Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
    Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Crizotinib-induced lichenoid drug eruption in a patient with lung cancer.
    Ho YH; Chen CL
    Cutis; 2018 Dec; 102(6):403-406. PubMed ID: 30657798
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Crizotinib-Induced Fulminant Hepatic Failure: A Rare Adverse Event.
    Adhikari N; Kumar P; Venkatesulu BP; Pandey R; Haresh KP; Gupta S; Sharma DN; Rath GK
    J Glob Oncol; 2018 Sep; 4():1-4. PubMed ID: 30241172
    [No Abstract]   [Full Text] [Related]  

  • 30. Accurate, fast, and convenient measurement of glomerular filtration rate in potential renal transplant donors.
    Rabito C; Halpern EF; Scott J; Tolkoff-Rubin N
    Transplantation; 2010 Sep; 90(5):510-7. PubMed ID: 20595931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.
    Duruisseaux M; Besse B; Cadranel J; Pérol M; Mennecier B; Bigay-Game L; Descourt R; Dansin E; Audigier-Valette C; Moreau L; Hureaux J; Veillon R; Otto J; Madroszyk-Flandin A; Cortot A; Guichard F; Boudou-Rouquette P; Langlais A; Missy P; Morin F; Moro-Sibilot D
    Oncotarget; 2017 Mar; 8(13):21903-21917. PubMed ID: 28423535
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
    Peters S; Camidge DR; Shaw AT; Gadgeel S; Ahn JS; Kim DW; Ou SI; Pérol M; Dziadziuszko R; Rosell R; Zeaiter A; Mitry E; Golding S; Balas B; Noe J; Morcos PN; Mok T;
    N Engl J Med; 2017 Aug; 377(9):829-838. PubMed ID: 28586279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial.
    Schöffski P; Sufliarsky J; Gelderblom H; Blay JY; Strauss SJ; Stacchiotti S; Rutkowski P; Lindner LH; Leahy MG; Italiano A; Isambert N; Debiec-Rychter M; Sciot R; Van Cann T; Marréaud S; Nzokirantevye A; Collette S; Wozniak A
    Lancet Respir Med; 2018 Jun; 6(6):431-441. PubMed ID: 29669701
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Crizotinib and renal insufficiency: a case report and review of the literature.
    Martín Martorell P; Huerta Alvaro M; Solís Salguero MA; Insa Molla A
    Lung Cancer; 2014 Jun; 84(3):310-3. PubMed ID: 24703892
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [ALK-rearranged non-small cell lung cancer: how to optimize treatment with crizotinib in routine practice?].
    Audigier-Valette C; Girard N; Cortot AB; Mennecier B; Debieuvre D; Planchard D; Zalcman G; Moro-Sibilot D; Cadranel J; Barlesi F
    Bull Cancer; 2014 Sep; 101(9):823-31. PubMed ID: 25299566
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Crizotinib-induced fatal fulminant liver failure.
    van Geel RM; Hendrikx JJ; Vahl JE; van Leerdam ME; van den Broek D; Huitema AD; Beijnen JH; Schellens JH; Burgers SA
    Lung Cancer; 2016 Mar; 93():17-9. PubMed ID: 26898609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer.
    Kang J; Chen HJ; Zhang XC; Su J; Zhou Q; Tu HY; Wang Z; Wang BC; Zhong WZ; Yang XN; Chen ZH; Ding Y; Wu X; Wang M; Fu JG; Yang Z; Zhang X; Shao YW; Wu YL; Yang JJ
    Thorac Cancer; 2018 Sep; 9(9):1093-1103. PubMed ID: 29978950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibitory Effect of Crizotinib on Creatinine Uptake by Renal Secretory Transporter OCT2.
    Arakawa H; Omote S; Tamai I
    J Pharm Sci; 2017 Sep; 106(9):2899-2903. PubMed ID: 28336299
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benefit of crizotinib in a lung cancer patient with discordant ALK testing results.
    Grocholski S; Banerji S; Qing G; Dawe DE
    Cancer Treat Res Commun; 2018; 15():13-16. PubMed ID: 30207282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer.
    Lin YT; Wang YF; Yang JC; Yu CJ; Wu SG; Shih JY; Yang PC
    J Thorac Oncol; 2014 Nov; 9(11):1720-5. PubMed ID: 25436806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.